MODERNA INC

NASDAQ: MRNA (Moderna, Inc.)

最近更新时间: 03 Jan, 12:37PM

41.75

-0.25 (-0.60%)

前收盘价格 42.00
收盘价格 42.20
成交量 3,279,647
平均成交量 (3个月) 7,642,422
市值 16,066,150,400
价格/销量 (P/S) 3.20
股市价格/股市净资产 (P/B) 1.36
52周波幅
35.80 (-14%) — 170.47 (308%)
利润日期 20 Feb 2025 - 24 Feb 2025
营业毛利率 -43.77%
营业利益率 (TTM) -3.76%
稀释每股收益 (EPS TTM) -5.81
季度收入增长率 (YOY) 1.70%
总债务/股东权益 (D/E MRQ) 11.36%
流动比率 (MRQ) 4.39
营业现金流 (OCF TTM) -3.21 B
杠杆自由现金流 (LFCF TTM) -3.34 B
资产报酬率 (ROA TTM) -9.55%
股东权益报酬率 (ROE TTM) -17.52%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Moderna, Inc. 看涨 看跌

AIStockmoo 评分

0.8
分析师共识 1.5
内部交易活动 -1.5
价格波动 4.5
技术平均移动指标 0.0
技术振荡指标 -0.5
平均 0.80

相关股票

股票 市值 DY P/E(TTM) P/B
MRNA 16 B - - 1.36
ALNY 32 B - - 993.29
XENE 3 B - - 3.83
VRTX 107 B - - 6.87
GMAB 14 B - 21.22 3.08
RPRX 18 B 2.80% 11.82 1.95

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

部门 Healthcare
行业 Biotechnology
投资方式 Mid Core
内部持股比例 9.52%
机构持股比例 71.64%

所有权

姓名 日期 持有股份
Theleme Partners Llp 30 Sep 2024 7,226,861
Flagship Pioneering Inc. 30 Sep 2024 4,632,149
Banque Pictet & Cie Sa 30 Sep 2024 3,155,399
52周波幅
35.80 (-14%) — 170.47 (308%)
目标价格波幅
38.00 (-8%) — 111.00 (165%)
111.00 (Barclays, 165.87%) 购买
51.50 (23.35%)
38.00 (Morgan Stanley, -8.98%) 保留
平均值 62.25 (49.10%)
总计 4 购买, 1 保留, 3 卖出
平均价格@调整类型 40.49
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 15 Jan 2025 38.00 (-8.98%) 保留 34.46
UBS 08 Jan 2025 96.00 (129.94%) 购买 43.17
24 Oct 2024 108.00 (158.68%) 购买 52.80
B of A Securities 10 Dec 2024 41.00 (-1.80%) 卖出 41.51
JP Morgan 26 Nov 2024 45.00 (7.78%) 卖出 42.05
04 Nov 2024 59.00 (41.32%) 卖出 53.54
HSBC 18 Nov 2024 58.00 (38.92%) 购买 39.51
Piper Sandler 18 Nov 2024 69.00 (65.27%) 购买 39.51
Wolfe Research 15 Nov 2024 40.00 (-4.19%) 卖出 36.85
Barclays 08 Nov 2024 111.00 (165.87%) 购买 46.83

该时间范围内无数据。

日期 类型 细节
13 Jan 2025 公告 Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
13 Jan 2025 CNBC Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion
05 Dec 2024 公告 BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho
25 Nov 2024 公告 Moderna to Present at Upcoming Conferences in December 2024
14 Nov 2024 CNBC Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
12 Nov 2024 公告 Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
08 Nov 2024 公告 Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
08 Nov 2024 公告 Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
07 Nov 2024 公告 Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
07 Nov 2024 CNBC Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold 
06 Nov 2024 CNBC Trump says he will give RFK Jr. a major health role. Here's what that means for patients, drugmakers
05 Nov 2024 公告 Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
31 Oct 2024 公告 Moderna to Present at Upcoming Conferences in November 2024
28 Oct 2024 公告 Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
24 Oct 2024 公告 Moderna Named a Top Employer by Science for Tenth Consecutive Year
23 Oct 2024 公告 Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
17 Oct 2024 公告 Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票